Reference is made to the stock exchange release from SoftOx Solutions AS (the "Company") on 6 July 2026 regarding the board resolution to increase the share capital by carrying out a private placement and debt conversion by issuing a total of 58 158 206 new shares at a subscription price of NOK 0,105 per share.
The new share capital following completion of the private placement and debt conversion has been registered with the Norwegian Register of Business Enterprises.
The new share capital of the Company is NOK 53 199 114.46 divided into 2 659 955 723 shares, each with a par value of NOK 0.02.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87 Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective therapy for the treatment of respiratory infections in the airways and lungs. The Company is listed on Euronext Growth Oslo.